LPL Financial’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$35M Buy
386,755
+33,164
+9% +$2.78M 0.01% 1212
2026
Q1
$28.3M Buy
353,591
+119,756
+51% +$9.87M 0.01% 1242
2025
Q4
$19.9M Buy
233,835
+16,826
+8% +$1.38M 0.01% 1412
2025
Q3
$16.9M Sell
217,009
-87,774
-29% -$6.86M ﹤0.01% 1468
2025
Q2
$23.8M Sell
304,783
-19,568
-6% -$1.46M 0.01% 1140
2025
Q1
$23.5M Buy
324,351
+62,671
+24% +$4.49M 0.01% 1055
2024
Q4
$19.4M Buy
261,680
+21,219
+9% +$1.49M 0.01% 1113
2024
Q3
$15.9M Sell
240,461
-81,890
-25% -$5.95M 0.01% 1167
2024
Q2
$29.8M Buy
322,351
+927
+0.3% +$82.1K 0.01% 791
2024
Q1
$30.7M Buy
321,424
+13,489
+4% +$1.13M 0.02% 746
2023
Q4
$23.5M Buy
307,935
+5,794
+2% +$403K 0.01% 813
2023
Q3
$20.9M Buy
302,141
+6,980
+2% +$561K 0.01% 786
2023
Q2
$27.8M Buy
295,161
+25,324
+9% +$2.2M 0.02% 654
2023
Q1
$22.3M Buy
269,837
+7,951
+3% +$625K 0.02% 714
2022
Q4
$19.5M Buy
261,886
+530
+0.2% +$40.8K 0.02% 724
2022
Q3
$21.6M Buy
261,356
+3,404
+1% +$328K 0.02% 619
2022
Q2
$24.5M Sell
257,952
-18,967
-7% -$1.96M 0.02% 568
2022
Q1
$32.6M Sell
276,919
-8,440
-3% -$947K 0.03% 484
2021
Q4
$37M Buy
285,359
+21,931
+8% +$2.56M 0.03% 444
2021
Q3
$29.8M Buy
263,428
+28,676
+12% +$3.27M 0.03% 479
2021
Q2
$24.3M Buy
234,752
+1,749
+0.8% +$165K 0.02% 519
2021
Q1
$19.5M Sell
233,003
-1,855
-0.8% -$157K 0.02% 562
2020
Q4
$21.4M Buy
234,858
+32,398
+16% +$2.69M 0.03% 454
2020
Q3
$16.2M Buy
202,460
+12,270
+6% +$957K 0.03% 462
2020
Q2
$13.1M Buy
190,190
+23,567
+14% +$1.67M 0.02% 497
2020
Q1
$10.5M Buy
166,623
+16,626
+11% +$1.2M 0.02% 487
2019
Q4
$11.7M Buy
149,997
+45,444
+43% +$3.55M 0.02% 529
2019
Q3
$7.66M Buy
104,553
+3,783
+4% +$266K 0.02% 628
2019
Q2
$6.21M Buy
100,770
+12,558
+14% +$759K 0.01% 700
2019
Q1
$5.63M Buy
88,212
+4,368
+5% +$249K 0.01% 709
2018
Q4
$4.28M Buy
83,844
+32,373
+63% +$1.64M 0.01% 745
2018
Q3
$2.99M Buy
51,471
+4,545
+10% +$222K 0.01% 956
2018
Q2
$2.28M Sell
46,926
-8,895
-16% -$415K 0.01% 1055
2018
Q1
$2.6M Buy
55,821
+6,480
+13% +$281K 0.01% 969
2017
Q4
$1.85M Buy
49,341
+3,528
+8% +$129K 0.01% 1121
2017
Q3
$1.67M Buy
45,813
+186
+0.4% +$7.09K 0.01% 1094
2017
Q2
$1.8M Sell
45,627
-10,005
-18% -$365K 0.01% 1007
2017
Q1
$1.75M Sell
55,632
-18,534
-25% -$580K 0.01% 911
2016
Q4
$2.36M Buy
74,166
+27,882
+60% +$903K 0.02% 720
2016
Q3
$1.84M Sell
46,284
-3,822
-8% -$144K 0.02% 816
2016
Q2
$1.73M Sell
50,106
-79,782
-61% -$2.73M 0.01% 835
2016
Q1
$4.47M Buy
129,888
+1,314
+1% +$36.3K 0.01% 779
2015
Q4
$3.43M Buy
128,574
+44,082
+52% +$1.14M 0.01% 884
2015
Q3
$2.1M Sell
84,492
-20,070
-19% -$484K 0.01% 813
2015
Q2
$2.53M Buy
104,562
+15,234
+17% +$344K 0.01% 791
2015
Q1
$2.1M Buy
89,328
+25,836
+41% +$580K 0.01% 887
2014
Q4
$1.35M Buy
63,492
+16,500
+35% +$331K 0.01% 1107
2014
Q3
$810K Sell
46,992
-10,950
-19% -$173K ﹤0.01% 1420
2014
Q2
$829K Buy
57,942
+9,384
+19% +$127K ﹤0.01% 1459
2014
Q1
$600K Sell
48,558
-68,280
-58% -$788K ﹤0.01% 1599
2013
Q4
$1.28M Sell
116,838
-19,248
-14% -$217K 0.01% 1089
2013
Q3
$1.7M Buy
+136,086
New +$1.59M 0.01% 874

Other funds holding EW

LPL Financial's EW Position: Q2 2026 in Review

LPL Financial increased its Edwards Lifesciences (EW) stake by 9.4% in Q2 2026, buying an estimated $2.78M and bringing the position to 386,755 shares worth $35M. The position accounts for 0.01% of the portfolio, ranked #1212.

LPL Financial first reported a position in EW in Q3 2013 and has held it in 52 quarters since. The position peaked at $37M in Q4 2021. 774 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • LPL Financial held 386,755 shares of Edwards Lifesciences worth $35M as of Q2 2026.
  • LPL Financial bought 33,164 Edwards Lifesciences shares in Q2 2026, an estimated $2.78M.
  • Edwards Lifesciences made up 0.01% of LPL Financial's portfolio in Q2 2026, its #1212 holding.
  • LPL Financial first reported a position in Edwards Lifesciences in Q3 2013 and has held it in 52 quarters since.
  • LPL Financial's Edwards Lifesciences position peaked at $37M in Q4 2021.
  • 774 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.